About This Event
Earlier this summer, the Novartis case pitted advocates of intellectual property rights for global pharmaceutical firms operating in India against those championing for more affordable drugs for patients in the developing world. Moreover, the recent and high-profile Ranbaxy case with the Federal Drug Administration raises questions about the safety and quality of Indian generics, even as some nongovernmental organizations (NGOs) champion generics as the best way to ensure that patients in poor countries get access to life-saving drugs at affordable prices.
At this conference, leading business sector, think-tank, and NGO representatives will examine the Indian pharmaceutical issue from the medical, business, and development perspectives.
If you are unable to attend, we welcome you to watch the event live on this page. Full video will be posted within 24 hours.
Agenda
9:45 AM
Registration
10:00 AM
Panel I: Economics and Intellectual Property Law
Panelists:
Roger Bate, AEI
Diane Farrell, U.S.-India Business Council
Arvind Subramanian, Peterson Institute for International Economics
Moderator:
Sadanand Dhume, AEI
1:00 PM
Panel II: Medicine Quality and Access
Panelists:
Gregg Alton, Gilead Sciences Inc.
Roger Bate, AEI
Douglas Keene, Management Sciences for Health
Andreas Seiter, World Bank
Moderator:
Aparna Mathur, AEI
2:30 PM
Adjournment
Event Contact Information
For more information, please contact Hao Fu at hao.fu@aei.org, 202.862.5214.
Media Contact Information
For media inquiries, please contact MediaServices@aei.org, 202.862.5829.
Fashion Island shooting Victor Cruz nfl standings Vicki Soto Adam Lanza cnbc Sandy Hook Victims
No comments:
Post a Comment